Buscar
Mostrando ítems 51-60 de 234
Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis
(2017)
Therapy for nonalcoholic steatohepatitis (NASH) is limited. Andrographolide (ANDRO), a botanical compound, has a potent anti-inflammatory activity due to its ability to inhibit NF-kB. ANDRO has been also shown to inhibit ...
Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis
(2017)
Therapy for nonalcoholic steatohepatitis (NASH) is limited. Andrographolide (ANDRO), a botanical compound, has a potent anti-inflammatory activity due to its ability to inhibit NF-kB. ANDRO has been also shown to inhibit ...
Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum.
(Lippincott Williams & Wilkins, 2014)
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
(2015)
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of hepatic histopathological changes ranging from non-inflammatory intracellular fat deposition to non-alcoholic steatohepatitis (NASH), which may progress ...
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
(2015)
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of hepatic histopathological changes ranging from non-inflammatory intracellular fat deposition to non-alcoholic steatohepatitis (NASH), which may progress ...
Effects of oral administration of silymarin in a juvenile murine model of non-alcoholic steatohepatitis
(Molecular Diversity Preservation International, 2017-09)
The increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in adolescents is challenging the global care system. No therapeutic strategies have been defined so far, and changes in the lifestyle remain the only ...
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
(BioMed CentralLondon, 2013)
Background
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease, which includes a spectrum of hepatic pathology such as simple steatosis, steatohepatitis, fibrosis and cirrhosis. The increased serum levels ...
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
(Biomed Central Ltd, 2013-04-02)
Background: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease, which includes a spectrum of hepatic pathology such as simple steatosis, steatohepatitis, fibrosis and cirrhosis. the increased serum levels ...
P-114 Liver transplantation for non-alcoholic steatohepatitis: outcomes in the main transplant center in Peru
(Fundación Clínica Médica Sur, 2021-09)
La prevalencia de EHNA postrasplante hepático es alta en el Perú. La recurrencia de MAFLD/NASH posterior al trasplante fue mayor que los casos de novo y el IMC fue alto en este grupo.